Quarterly report pursuant to Section 13 or 15(d)

COMMITMENTS AND CONTINGENCIES (Details Narrative)

v3.20.1
COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended
Apr. 30, 2020
Mar. 28, 2019
Dec. 10, 2015
Mar. 31, 2020
Dec. 31, 2019
May 30, 2019
Research and development expenses       $ 949,670    
Description for compensation for services under agreement       (i) one consultant shall receive a renumeration amount of $10,000-$12,500 per month with an earn out potential of 1% of the Companys majority owned subsidiary, BioCorRx Pharmaceuticals based on certain factors. (ii) one consultant shall receive common stock equivalent to $1,375 on the last day of each month; and (iii) one consultant shall receive common stock equivalent to $6,667 on the last day of each month (iv) one consultant shall receive a renumeration amount of $5,500 per month    
Common stock issued upon convertible debt       2,227,575    
Common stock shares issued for services          
Lucido [Member]            
Common stock, Shares issued   200,000        
Alpine Creek [Member]            
Payables to Alpine Creek     $ 1,215,000   $ 85,805  
Payable commitment description     In the event that the Company has not paid Alpine Creek $1,215,000 within 24 months of the Effective Date, then the Company shall continue to pay Alpine Creek fifty percent (50%) for each Treatment following the Effective Date until the Company has paid Alpine Creek an aggregate of $1,620,000, with the exception of treatments conducted in certain territories On any other proprietary implant distribution, that excludes the “treatment”, for alcohol and opioid addiction and for which no other payment is due, the Company shall pay 2.5% of the Companys gross profit for implant distribution not to exceed $100 per sale    
Payable per treatment sold     $ 100      
Royalty due       $ 144 $ 3,503  
Profit holding percentage     50.00%      
BICX Holding Company LLC [Member]            
Common stock issued upon convertible debt       2,227,575    
Convertible Promissory Note       $ 4,160,000    
Conversion agreement description       Pursuant to the Conversion Agreement, BICX has agreed that the Total Interest Payment (as defined in the Conversion Agreement) that would have been due under the Note, in the amount of $1,138,157, will be reflected on the Companys financial statements as an amount due and owing to the Investor to be repaid within twelve (12) months of the closing of the Public Offering, or if the Public Offering is terminated or abandoned prior to closing, then on or before such date that is no later than twelve (12) months from the date of such termination or abandonment    
Issuance price       $ 2.00    
Gross proceeds       $ 10,000,000    
Charles River Laboratories, Inc. [Member]            
Consideration amount       $ 1,691,891   $ 3,024,476
Galligan Subscription and Royalty Agreement [Member]            
Ownership percentage by holder       5.00%    
Ownership percentage held by Company       10.00%    
Common stock, Shares issued   200,000        
Manufacturing Agreement [Member]            
Research and development expenses       $ 119,000    
Consideration amount       224,648    
Estimated cost       578,500    
Lucido Subscription and Royalty Agreement [Member]            
Development and expansion expenses amount       3,000,000    
Subscription and royalty agreement description   Pursuant to the Lucido Subscription and Royalty Agreement: (i) Mr. Lucido purchased shares of the Companys common stock, par value $0.001 per share (the “Common Stock”), in the aggregate amount of $3,000,000 at a purchase price of $15.00 per share (the “Purchase Price”), for a total of 200,000 shares of Common Stock; and (ii) the Company shall pay Lucido (a) a total of $37.50 from the gross revenue derived from each of its weight loss treatments sold in the United States starting on the first (1st) day that the first unit of the treatment is sold (the “Initial Sales Date”) and ending on the third (3rd) anniversary of the Initial Sales Date; and (b) a total of $25.00 from the gross revenue derived from each of its weight loss treatments sold in the United States starting on the day following the third (3rd) anniversary of the Initial Sales Date and ending on the fifteenth (15th) anniversary of the Initial Sales Date (the “Royalty”)        
Description for the use of proceeds under agreement   The Company will use no less than 65% of the proceeds of the aggregate Purchase Price of the Lucido Subscription and Royalty Agreement exclusively to develop, launch and expand the Companys weight loss program (the “Business”) including sales and marketing activities directly related to the Business, and shall be free to use up to 35% of the aggregate Purchase Price of the Lucido Subscription and Royalty Agreement for general working capital and administration, and for further product development. With the prior written consent of Mr. Lucido, the Company may use more than 35% of the aggregate Purchase Price for general working capital and administration, and for further product development        
March 31, 2020 [Member] | Sinclair Research Center LLC [Member]            
Research and development expenses       357,840    
Consideration amount       536,760    
February 20, 2020 [Member] | Statement of Work Pursuant [Member]            
Consideration amount       894,600    
Subsequent Event [Member]            
Common stock shares issued for services 9,204          
Common stock shares issued to each consultant for services, value $ 18,040          
Subsequent Event [Member] | May 13, 2020 [Member] | two scientific advisory board agreements [Member]            
Common stock shares issued to each consultant for services, value       5,000    
Shares reserved for future issuance, value       $ 5,000